uniQure N.V. 
QURE is a leading gene therapy biotech targeting rare diseases like Huntington’s and hemophilia.
🔹 Bullish setup forming above $14.50–$15.00
🔹 Price Target: $28.00–$29.00
📈 Catalyst: FDA alignment on its Huntington’s program (AMT-130) clears the path for a BLA submission in Q1 2026, significantly derisking the development.
✅ Early data from AMT-130 is promising, tracking well with clinical and biomarker endpoints — potential first-mover in disease-modifying therapies for Huntington’s.
🧠 Expanding platform: AMT-260 (epilepsy) delivered a 92% seizure reduction in initial patient, showcasing pipeline breadth across CNS disorders.
🧬 QURE offers exposure to the fast-growing gene therapy space with high long-term upside potential if clinical momentum continues.
#QURE #GeneTherapy #BiotechStocks #FDA #BreakoutSetup #LongSetup #RareDiseases #HuntingtonsDisease #Epilepsy #SmallCapStocks #GrowthStocks #Healthcare #BiotechInvesting #TechnicalAnalysis #StockWatchlist #Bullish
QURE is a leading gene therapy biotech targeting rare diseases like Huntington’s and hemophilia.🔹 Bullish setup forming above $14.50–$15.00
🔹 Price Target: $28.00–$29.00
📈 Catalyst: FDA alignment on its Huntington’s program (AMT-130) clears the path for a BLA submission in Q1 2026, significantly derisking the development.
✅ Early data from AMT-130 is promising, tracking well with clinical and biomarker endpoints — potential first-mover in disease-modifying therapies for Huntington’s.
🧠 Expanding platform: AMT-260 (epilepsy) delivered a 92% seizure reduction in initial patient, showcasing pipeline breadth across CNS disorders.
🧬 QURE offers exposure to the fast-growing gene therapy space with high long-term upside potential if clinical momentum continues.
#QURE #GeneTherapy #BiotechStocks #FDA #BreakoutSetup #LongSetup #RareDiseases #HuntingtonsDisease #Epilepsy #SmallCapStocks #GrowthStocks #Healthcare #BiotechInvesting #TechnicalAnalysis #StockWatchlist #Bullish
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。